Table 1.

Clinical characteristics of patients with CRE positive in this study.

Clinical characteristics	CRE colonization group (n = 96)	CRE infection group (n = 70)	P-value*
Male sex	56 (58.3%)	38 (54.3%)	0.603
Age in months (median)	12 m	1 m	0.010
Isolation wards
Neonatology dept.	33 (34.4%)	45 (64.3%)	<0.001
General medicine	18 (18.8%)	6 (8.6%)	0.066
PICU	17 (17.7%)	11 (15.7%)	0.735
Hematology department	16 (16.7%)	3 (4.3%)	0.013
Respiratory department	6 (6.3%)	1 (1.4%)	0.127
Others	6 (6.3%)	4 (5.7%)	0.886
Underlying diseases
Pneumonia	58 (60.4%)	48 (68.6%)	0.280
Sepsis	23 (24.0%)	25 (35.7%)	0.099
Gastrointestinal infections	37 (38.5%)	7 (10.0%)	<0.001
UTI	5 (5.2%)	6 (8.6%)	0.390
Cephalomeningitis	4 (4.2%)	7 (10.0%)	0.136
Hospitalization stays (median)	11 days	37 days	0.079
Recent hospitalization history	39 (40.6%)	21 (30.0%)	0.159
Invasive procedures	48 (50.0%)	59 (84.2%)	<0.001
Antibiotic exposures
β-lactam/β-lactamase inhibitor	44 (45.8%)	41 (58.6%)	0.105
Cephalosporins	63 (65.6%)	36 (51.4%)	0.066
Carbapenems	35 (36.5%)	39 (55.7%)	0.014
CRE infection	14 (14.6%)	–	–
Clinical outcome
Improved	63 (65.6%)	66 (94.3%)	<0.001
Unhealed	31 (32.3%)	2 (2.9%)	0.000
Died	2 (2.1%)	2 (2.9%)	0.748

^*A comparison between two groups. A P-value of ue. A on between inhibitorstically significant.

CRE, Carbapenem-resistant Enterobacteriales, PICU, pediatric intensive care unit; UTI, urinary tract infection.